Cytokines in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus: A Companion to Rheumatology

Volumn , Issue , 2007, Pages 109-120

  Rus, Violeta ^a   Via, Charles S ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954541953     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-04434-9.50017-8     Document Type: Chapter

References (159)

1. Tsokos GC Overview of cellular immune function in systemic lupus erythematosus. Systemic Lupus Erythematosus, Fourth Edition 2004, 29. Academic Press, San Diego. R.G. Lahita (Ed.).
2. Handwerger BS, Rus V, da Silva L, et al. The role of cytokines in the immunopathogenesis of lupus. Springer Semin Immunopathol 1994, 16:153.
3. Froncek MJ, Horwitz DA Cytokines in the pathogenesis of systemic lupus erythematosus. Dubois' Lupus Erythematosus, Sixth Edition 2002, 187. Lippincott Williams & Wilkins, Philadelphia. D.J. Wallace, B.H. Hahn (Eds.).
4. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136:2348.
5. Finkelman FD, Katona IM, Mosmann TR, et al. IFN-gamma regulates the isotypes of Ig secreted during in vivo humoral immune responses. J Immunol 1988, 140:1022.
6. Hwang ES, Hong JH, Glimcher LH IL-2 production in developing Th1 cells is regulated by heterodimerization of RelA and T-bet and requires T-bet serine residue 508. J Exp Med 2005, 202:1289.
7. Via CS, Shustov A, Rus V, et al. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 2001, 167:6821.
8. Tsokos GC, Balow JE Cellular immune responses in systemic lupus erythematosus. Prog Allergy 1984, 35:93.
9. Kammer GM Altered regulation of IL-2 production in systemic lupus erythematosus: An evolving paradigm. J Clin Invest 2005, 115:836.
10. Kammer GM, Perl A, Richardson BC, et al. Abnormal T cell signal transduction in systemic lupus erythematosus. Arthritis Rheum 2002, 46:1139.
11. Kyttaris VC, Juang YT, Tenbrock K, et al. Cyclic adenosine 5'-monophosphate response element modulator is responsible for the decreased expression of c-fos and activator protein-1 binding in T cells from patients with systemic lupus erythematosus. J Immunol 2004, 173:3557.
12. Via CS, Shearer GM T-cell interactions in autoimmunity: Insights from a murine model of graft-versus-host disease. Immunol Today 1988, 9:207.
13. Via CS, Sharrow SO, Shearer GM Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease. J Immunol 1987, 139:1840.
14. Juang YT, Wang Y, Solomou EE, et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest 2005, 115:996.
15. Celis E, Miller RW, Wiktor TJ, et al. Isolation and characterization of human T cell lines and clones reactive to rabies virus: Antigen specificity and production of interferon-gamma. J Immunol 1986, 136:692.
16. Farrar MA, Schreiber RD The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 1993, 11:571.
17. Ozmen L, Roman D, Fountoulakis M, et al. Experimental therapy of systemic lupus erythematosus: The treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis. Eur J Immunol 1995, 25:6.
18. Jacob CO, van der Meide PH, McDevitt HO In vivo treatment of (NZB × NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med 1987, 166:798.
19. Lawson BR, Prud'homme GJ, Chang Y, et al. Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc. J Clin Invest 2000, 106:207.
20. Nicoletti F, Di Marco R, Zaccone P, et al. Dichotomic effects of IFN-gamma on the development of systemic lupus erythematosus-like syndrome in MRL-lpr / lpr mice. Eur J Immunol 2000, 30:438.
21. Puliaev R, Nguyen P, Finkelman FD, et al. Differential requirement for IFN-gamma in CTL maturation in acute murine graftversus-host disease. J Immunol 2004, 173:910.
22. al-Janadi M, al-Balla S, al-Dalaan A, et al. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol 1993, 13:58.
23. Robak E, Sysa-Jedrzejewska A, Dziankowska B, et al. Association of interferon gamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity. Arch Immunol Ther Exp (Warsz) 1998, 46:375.
24. Csiszar A, Nagy G, Gergely P, et al. Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 2000, 122:464.
25. Lu L, Kaliyaperumal A, Boumpas DT, et al. Major peptide autoepitopes for nucleosome-specific T cells of human lupus. J Clin Invest 1999, 104:345.
26. Stolzenburg T, Binz H, Fontana A, et al. Impaired mitogen-induced interferon-gamma production in rheumatoid arthritis and related diseases. Scand J Immunol 1988, 27:73.
27. Tsokos GC, Boumpas DT, Smith PL, et al. Deficient gamma-interferon production in patients with systemic lupus erythematosus. Arthritis Rheum 1986, 29:1210.
28. Viallard JF, Pellegrin JL, Ranchin V, et al. Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1999, 115:189.
29. Hagiwara E, Gourley MF, Lee S, et al. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum 1996, 39:379.
30. Min DJ, Cho ML, Cho CS, et al. Decreased production of interleukin-12 and interferon-gamma is associated with renal involvement in systemic lupus erythematosus. Scand J Rheumatol 2001, 30:159.
31. Tanaka Y, Nakashima H, Hisano C, et al. Association of the interferon-gamma receptor variant (Val14Met) with systemic lupus erythematosus. Immunogenetics 1999, 49:266.
32. Nakashima H, Inoue H, Akahoshi M, et al. The combination of polymorphisms within interferon-gamma receptor 1 and receptor 2 associated with the risk of systemic lupus erythematosus. FEBS Lett 1999, 453:187.
33. Hooks JJ, Moutsopoulos HM, Geis SA, et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979, 301:5.
34. Ytterberg SR, Schnitzer TJ Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982, 25:401.
35. Bengtsson AA, Sturfelt G, Truedsson L, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000, 9:664.
36. Ronnblom LE, Alm GV, Oberg KE Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991, 115:178.
37. Crow MK, Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res Ther 2003, 5:279.
38. Kirou KA, Lee C, George S, et al. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005, 52:1491.
39. Santiago-Raber ML, Baccala R, Haraldsson KM, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003, 197:777.
40. Mathian A, Weinberg A, Gallegos M, et al. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White) F1 but not in BALB/c mice. J Immunol 2005, 174:2499.
41. Ronnblom L, Alm GV A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 2001, 194:F59.
42. Cederblad B, Blomberg S, Vallin H, et al. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha-producing cells. J Autoimmun 1998, 11:465.
43. Blomberg S, Eloranta ML, Cederblad B, et al. Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 2001, 10:484.
44. Blanco P, Palucka AK, Gill M, et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001, 294:1540.
45. Le Bon A, Schiavoni G, D'Agostino G, et al. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001, 14:461.
46. Kirou KA, Vakkalanka RK, Butler MJ, et al. Induction of Fas ligand-mediated apoptosis by interferon-alpha. Clin Immunol 2000, 95:218.
47. Rus V, Zernetkina V, Puliaev R, et al. Increased expression and production of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by T cells from lupus patients is a feature of active disease. Clin Immunol 2005, 117:48.
48. Trinchieri G. Interleukin-12: A cytokine at the interface of inflammation and immunity. Adv Immunol 1998, 70:83.
49. Nakajima A, Hirose S, Yagita H, et al. Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice. J Immunol 1997, 158:1466.
50. Schmitt E, Rude E, Germann T. The immunostimulatory function of IL-12 in T-helper cell development and its regulation by TGF-beta, IFN-gamma and IL-4. Chem Immunol 1997, 68:70.
51. Metzger DW, McNutt RM, Collins JT, et al. Interleukin-12 acts as an adjuvant for humoral immunity through interferon-gamma-dependent and-independent mechanisms. Eur J Immunol 1997, 27:1958.
52. Tokano Y, Morimoto S, Kaneko H, et al. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)-relation to Th1-and Th2-derived cytokines. Clin Exp Immunol 1999, 116:169.
53. Horwitz DA, Gray JD, Behrendsen SC, et al. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum 1998, 41:838.
54. Liu TF, Jones BM, Wong RW, et al. Impaired production of IL-12 in systemic lupus erythematosus. III: Deficient IL-12 p40 gene expression and cross-regulation of IL-12, IL-10 and IFN-gamma gene expression. Cytokine 1999, 11:805.
55. Tsai CY, Wu TH, Yu CL, et al. Decreased IL-12 production by poly-morphonuclear leukocytes in patients with active systemic lupus erythematosus. Immunol Invest 2002, 31:177.
56. Liu TF, Jones BM Impaired production of IL-12 in system lupus erythematosus. II: IL-12 production in vitro is correlated negatively with serum IL-10, positively with serum IFN-gamma and negatively with disease activity in SLE. Cytokine 1998, 10:148.
57. Houssiau FA, Mascart-Lemone F, Stevens M, et al. IL-12 inhibits in vitro immunoglobulin production by human lupus peripheral blood mononuclear cells (PBMC). Clin Exp Immunol 1997, 108:375.
58. Via CS, Rus V, Gately MK, et al. IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease. J Immunol 1994, 153:4040.
59. Pollard KM, Hultman P, Kono DH Using single-gene deletions to identify checkpoints in the progression of systemic autoimmunity. Ann N Y Acad Sci 2003, 987:236.
60. Illera VA, Perandones CE, Stunz LL, et al. Apoptosis in splenic B lymphocytes. Regulation by protein kinase C and IL-4. J Immunol 1993, 151:2965.
61. Lutzker S, Rothman P, Pollock R, et al. Mitogen-and IL-4-regulated expression of germ-line Ig gamma 2b transcripts: Evidence for directed heavy chain class switching. Cell 1988, 53:177.
62. Morris SC, Gause WC, Finkelman FD IL-4 suppression of in vivo T cell activation and antibody production. J Immunol 2000, 164:1734.
63. Dueymes M, Barrier J, Besancenot JF, et al. Relationship of interleukin-4 to isotypic distribution of anti-double-stranded DNA antibodies in systemic lupus erythematosus. Int Arch Allergy Immunol 1993, 101:408.
64. Tanaka Y, Saito K, Shirakawa F, et al. Production of B cell-stimulating factors by B cells in patients with systemic lupus erythematosus. J Immunol 1988, 141:3043.
65. Lit L, Wong C, Tam L, et al. Elevated plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis 2006, 65:209.
66. Richaud-Patin Y, Alcocer-Varela J, Llorente L. High levels of TH2 cytokine gene expression in systemic lupus erythematosus. Rev Invest Clin 1995, 47:267.
67. Tan PL, Blumenstein M, Yeoman S, et al. B cell lymphokines in human systemic lupus erythematosus. Ann Rheum Dis 1989, 48:941.
68. Horwitz DA, Wang H, Gray JD Cytokine gene profile in circulating blood mononuclear cells from patients with systemic lupus erythematosus: Increased interleukin-2 but not interleukin-4 mRNA. Lupus 1994, 3:423.
69. Sugimoto K, Morimoto S, Kaneko H, et al. Decreased IL-4 producing CD4+ T cells in patients with active systemic lupus erythematosus-relation to IL-12R expression. Autoimmunity 2002, 35:381.
70. Kanemitsu S, Takabayashi A, Sasaki Y, et al. Association of interleukin-4 receptor and interleukin-4 promoter gene polymorphisms with systemic lupus erythematosus. Arthritis Rheum 1999, 42:1298.
71. Wu MC, Huang CM, Tsai JJ, et al. Polymorphisms of the interleukin-4 gene in chinese patients with systemic lupus erythematosus in Taiwan. Lupus 2003, 12:21.
72. Umland S, Lee R, Howard M, et al. Expression of lymphokine genes in splenic lymphocytes of autoimmune mice. Mol Immunol 1989, 26:649.
73. Davidson WF, Calkins C, Hugins A, et al. Cytokine secretion by C3H-lpr and-gld T cells. Hypersecretion of IFN-gamma and tumor necrosis factor-alpha by stimulated CD4+ T cells. J Immunol 1991, 146:4138.
74. Budd RC, Schumacher JH, Winslow G, et al. Elevated production of interferon-gamma and interleukin 4 by mature T cells from autoimmune lpr mice correlates with Pgp-1 (CD44) expression. Eur J Immunol 1991, 21:1081.
75. Okada H, Konishi K, Nakazato Y, et al. Interleukin-4 expression in mesangial proliferative glomerulonephritis. Am J Kidney Dis 1994, 23:242.
76. Furusu A, Miyazaki M, Koji T, et al. Involvement of IL-4 in human glomerulonephritis: An in situ hybridization study of IL-4 mRNA and IL-4 receptor mRNA. J Am Soc Nephrol 1997, 8:730.
77. Singh RR, Saxena V, Zang S, et al. Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis. J Immunol 2003, 170:4818.
78. Stein LF, Saed GM, Fivenson DP T-cell cytokine network in cutaneous lupus erythematosus. J Am Acad Dermatol 1997, 36:191.
79. Amel-Kashipaz MR, Huggins ML, Lanyon P, et al. Quantitative and qualitative analysis of the balance between type 1 and type 2 cytokine-producing CD8(-) and CD8(+) T cells in systemic lupus erythematosus. J Autoimmun 2001, 17:155.
80. Chen YY, Suen JL, Wu WM, et al. The effect of cytokines on the activation-induced apoptosis of B cells in autoimmune NZB × NZW F1 mice. Scand J Immunol 2001, 53:596.
81. Wen X, Zhang D, Kikuchi Y, et al. Transgene-mediated hyper-expression of IL-5 inhibits autoimmune disease but increases the risk of B cell chronic lymphocytic leukemia in a model of murine lupus. Eur J Immunol 2004, 34:2740.
82. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: From basic science to medicine. Arthritis Res 4 Suppl 2002, 3:S233.
83. Linker-Israeli M, Deans RJ, Wallace DJ, et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus: A putative role in pathogenesis. J Immunol 1991, 147:117.
84. Spronk PE, ter Borg EJ, Limburg PC, et al. Plasma concentration of IL-6 in systemic lupus erythematosus: An indicator of disease activity?. Clin Exp Immunol 1992, 90:106.
85. Ripley BJ, Goncalves B, Isenberg DA, et al. Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann Rheum Dis 2005, 64:849.
86. Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cere-brospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 1990, 33:644.
87. Peterson E, Robertson AD, Emlen W. Serum and urinary interleukin-6 in systemic lupus erythematosus. Lupus 1996, 5:571.
88. Horii Y, Iwano M, Hirata E, et al. Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis. Kidney Int Suppl 1993, 39:S71.
89. Nurnberg W, Haas N, Schadendorf D, et al. Interleukin-6 expression in the skin of patients with lupus erythematosus. Exp Dermatol 1995, 4:52.
90. Malide D, Russo P, Bendayan M. Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol 1995, 26:558.
91. Alcocer-Varela J, Aleman-Hoey D, Alarcon-Segovia D. Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers. Lupus 1992, 1:111.
92. Nagafuchi H, Suzuki N, Mizushima Y, et al. Constitutive expression of IL-6 receptors and their role in the excessive B cell function in patients with systemic lupus erythematosus. J Immunol 1993, 151:6525.
93. Kitani A, Hara M, Hirose T, et al. Heterogeneity of B cell responsiveness to interleukin 4, interleukin 6 and low molecular weight B cell growth factor in discrete stages of B cell activation in patients with systemic lupus erythematosus. Clin Exp Immunol 1989, 77:31.
94. Kobayashi I, Matsuda T, Saito T, et al. Abnormal distribution of IL-6 receptor in aged MRL/lpr mice: Elevated expression on B cells and absence on CD4+ cells. Int Immunol 1992, 4:1407.
95. Suzuki H, Yasukawa K, Saito T, et al. Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal. Eur J Immunol 1993, 23:1078.
96. Tang B, Matsuda T, Akira S, et al. Age-associated increase in interleukin 6 in MRL/lpr mice. Int Immunol 1991, 3:273.
97. Mihara M, Ohsugi Y. Possible role of IL-6 in pathogenesis of immune complex-mediated glomerulonephritis in NZB/W F1 mice: Induction of IgG class anti-DNA autoantibody production. Int Arch Allergy Appl Immunol 1990, 93:89.
98. Liu K, Liang C, Liang Z, et al. Sle1ab mediates the aberrant activation of STAT3 and Ras-ERK signaling pathways in B lymphocytes. J Immunol 2005, 174:1630.
99. Ryffel B, Car BD, Gunn H, et al. Interleukin-6 exacerbates glomerulonephritis in (NZB × NZW)F1 mice. Am J Pathol 1994, 144:927.
100. Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest 1994, 94:585.
101. Mihara M, Takagi N, Takeda Y, et al. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol 1998, 112:397.
102. Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683.
103. Rus V, Svetic A, Nguyen P, et al. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells. J Immunol 1995, 155:2396.
104. Horwitz DA, Jacob CO The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications. Springer Semin Immunopathol 1994, 16:181.
105. Houssiau FA, Lefebvre C, Vanden Berghe M, et al. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 1995, 4:393.
106. Park YB, Lee SK, Kim DS, et al. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998, 16:283.
107. Ishida H, Muchamuel T, Sakaguchi S, et al. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994, 179:305.
108. Llorente L, Zou W, Levy Y, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995, 181:839.
109. Kalechman Y, Gafter U, Da JP, et al. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels. J Immunol 1997, 159:2658.
110. Yin Z, Bahtiyar G, Zhang N, et al. IL-10 regulates murine lupus. J Immunol 2002, 169:2148.
111. Llorente L, Richaud-Patin Y, Couderc J, et al. Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. Arthritis Rheum 1997, 40:1429.
112. Lauwerys BR, Garot N, Renauld JC, et al. Interleukin-10 blockade corrects impaired in vitro cellular immune responses of systemic lupus erythematosus patients. Arthritis Rheum 2000, 43:1976.
113. Mongan AE, Ramdahin S, Warrington RJ Interleukin-10 response abnormalities in systemic lupus erythematosus. Scand J Immunol 1997, 46:406.
114. Llorente L, Richaud-Patin Y, Garcia-Padilla C, et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000, 43:1790.
115. Aotsuka S, Nakamura K, Nakano T, et al. Production of intracellular and extracellular interleukin-1 alpha and interleukin-1 beta by peripheral blood monocytes from patients with connective tissue diseases. Ann Rheum Dis 1991, 50:27.
116. Jandl RC, George JL, Silberstein DS, et al. The effect of adherent cell-derived factors on immunoglobulin and anti-DNA synthesis in systemic lupus erythematosus. Clin Immunol Immunopathol 1987, 42:344.
117. Andersen LS, Petersen J, Svenson M, et al. Production of IL-1beta, IL-1 receptor antagonist and IL-10 by mononuclear cells from patients with SLE. Autoimmunity 1999, 30:235.
118. Liou LB Serum and in vitro production of IL-1 receptor antagonist correlate with C-reactive protein levels in newly diagnosed, untreated lupus patients. Clin Exp Rheumatol 2001, 19:515.
119. Whicher JT, Gilbert AM, Westacott C, et al. Defective production of leucocytic endogenous mediator (interleukin 1) by peripheral blood leucocytes of patients with systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis and mixed connective tissue disease. Clin Exp Immunol 1986, 65:80.
120. Parks CG, Cooper GS, Dooley MA, et al. Systemic lupus erythematosus and genetic variation in the interleukin 1 gene cluster: A population based study in the southeastern United States. Ann Rheum Dis 2004, 63:91.
121. Huang CM, Wu MC, Wu JY, et al. Interleukin-1 receptor antagonist gene polymorphism in Chinese patients with systemic lupus erythematosus. Clin Rheumatol 2002, 21:255.
122. Scuderi F, Convertino R, Molino N, et al. Effect of pro-inflammatory/anti-inflammatory agents on cytokine secretion by peripheral blood mononuclear cells in rheumatoid arthritis and systemic lupus erythematosus. Autoimmunity 2003, 36:71.
123. Sturfelt G, Roux-Lombard P, Wollheim FA, et al. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. Br J Rheumatol 1997, 36:1283.
124. Moosig F, Zeuner R, Renk C, et al. IL-1RA in refractory systemic lupus erythematosus. Lupus 2004, 13:605.
125. Ostendorf B, Iking-Konert C, Kurz K, et al. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 2005, 64:630.
126. Jacob CO, Fronek Z, Lewis GD, et al. Heritable major histocom-patibility complex class II-associated differences in production of tumor necrosis factor alpha: Relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 1990, 87:1233.
127. Sullivan KE, Wooten C, Schmeckpeper BJ, et al. A promoter polymorphism of tumor necrosis factor alpha associated with systemic lupus erythematosus in African-Americans. Arthritis Rheum 1997, 40:2207.
128. van der Linden MW, van der Slik AR, Zanelli E, et al. Six microsatellite markers on the short arm of chromosome 6 in relation to HLA-DR3 and TNF-308A in systemic lupus erythematosus. Genes Immun 2001, 2:373.
129. Zuniga J, Vargas-Alarcon G, Hernandez-Pacheco G, et al. Tumor necrosis factor-alpha promoter polymorphisms in Mexican patients with systemic lupus erythematosus (SLE). Genes Immun 2001, 2:363.
130. Rudwaleit M, Tikly M, Khamashta M, et al. Interethnic differences in the association of tumor necrosis factor promoter polymorphisms with systemic lupus erythematosus. J Rheumatol 1996, 23:1725.
131. Hajeer AH, Worthington J, Davies EJ, et al. TNF microsatellite a2, b3 and d2 alleles are associated with systemic lupus erythematosus. Tissue Antigens 1997, 49:222.
132. Takeuchi F, Nabeta H, Hong GH, et al. The genetic contribution of the TNFa11 microsatellite allele and the TNFb + 252*2 allele in Japanese RA. Clin Exp Rheumatol 2005, 23:494.
133. Al-Ansari AS, Ollier WE, Villarreal J, et al. Tumor necrosis factor receptor II (TNFRII) exon 6 polymorphism in systemic lupus erythematosus. Tissue Antigens 2000, 55:97.
134. Deguchi Y, Kishimoto S. Tumour necrosis factor/cachectin plays a key role in autoimmune pulmonary inflammation in lupus-prone mice. Clin Exp Immunol 1991, 85:392.
135. Gordon C, Ranges GE, Greenspan JS, et al. Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol 1989, 52:421.
136. Brennan DC, Yui MA, Wuthrich RP, et al. Tumor necrosis factor and IL-1 in New Zealand Black/White mice: Enhanced gene expression and acceleration of renal injury. J Immunol 1989, 143:3470.
137. Maury CP, Teppo AM Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum 1989, 32:146.
138. Studnicka-Benke A, Steiner G, Petera P, et al. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996, 35:1067.
139. Mitamura K, Kang H, Tomita Y, et al. Impaired tumour necrosis factor-alpha (TNF-alpha) production and abnormal B cell response to TNF-alpha in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1991, 85:386.
140. Jones BM, Liu T, Wong RW Reduced in vitro production of interferon-gamma, interleukin-4 and interleukin-12 and increased production of interleukin-6, interleukin-10 and tumour necrosis factor-alpha in systemic lupus erythematosus. Weak correlations of cytokine production with disease activity. Autoimmunity 1999, 31:117.
141. Meijer C, Huysen V, Smeenk RT, et al. Profiles of cytokines (TNF alpha and IL-6) and acute phase proteins (CRP and alpha 1AG) related to the disease course in patients with systemic lupus erythematosus. Lupus 1993, 2:359.
142. Feldmann M, Maini RN Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu Rev Immunol 2001, 19:163.
143. Mohan AK, Edwards ET, Cote TR, et al. Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet 2002, 360:646.
144. Palucka AK, Blanck JP, Bennett L, et al. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 2005, 102:3372.
145. Aringer M, Graninger WB, Steiner G, et al. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: An open-label study. Arthritis Rheum 2004, 50:3161.
146. Letterio JJ, Roberts AB Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998, 16:137.
147. Gray JD, Hirokawa M, Horwitz DA The role of transforming growth factor beta in the generation of suppression: An interaction between CD8+ T and NK cells. J Exp Med 1994, 180:1937.
148. Zheng SG, Gray JD, Ohtsuka K, et al. Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25-precursors. J Immunol 2002, 169:4183.
149. Yamagiwa S, Gray JD, Hashimoto S, et al. A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J Immunol 2001, 166:7282.
150. Sporn MB, Roberts AB Autocrine secretion-10 years later. Ann Intern Med 1992, 117:408.
151. Kehrl JH, Wakefield LM, Roberts AB, et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986, 163:1037.
152. Brabletz T, Pfeuffer I, Schorr E, et al. Transforming growth factor beta and cyclosporin A inhibit the inducible activity of the interleukin-2 gene in T cells through a noncanonical octamer-binding site. Mol Cell Biol 1993, 13:1155.
153. Espevik T, Figari IS, Shalaby MR, et al. Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J Exp Med 1987, 166:571.
154. Cerwenka A, Bevec D, Majdic O, et al. TGF-beta 1 is a potent inducer of human effector T cells. J Immunol 1994, 153:4367.
155. Ohtsuka K, Gray JD, Stimmler MM, et al. Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus. J Immunol 1998, 160:2539.
156. Ohtsuka K, Gray JD, Stimmler MM, et al. The relationship between defects in lymphocyte production of transforming growth factor-beta1 in systemic lupus erythematosus and disease activity or severity. Lupus 1999, 8:90.
157. Crispin JC, Martinez A, Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2003, 21:273.
158. Glas-Greenwalt P, Kant KS, Dosekun A, et al. Ancrod: Normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis. J Lab Clin Med 1985, 105:99.
159. Christ M, McCartney-Francis NL, Kulkarni AB, et al. Immune dys-regulation in TGF-beta 1-deficient mice. J Immunol 1994, 153:1936.